|
목적 : Although multiple medications are frequently required to lower intraocular pressure (IOP), evidence supporting use of fixed-combination brimonidine tartrate 0.2%/timolol 0.5% (FCBT; Combigan®, Allergan plc) in POAG including NTG is limited. This study assessed the efficacy and safety of FCBT alone or with bimatoprost 0.01% (Lumigan®, Allergan plc) in POAG including NTG.
방법 : FCBT was administered twice/day in the study eye (after prior therapy washout). Bimatoprost could be added if IOP reduction was <20%. Outcomes: mean IOP change from baseline at month 12 (11 AM, primary; 9 AM, secondary), visual field (VF) progression rate (per the VF index), time to achieving target IOP, and adverse events (AEs).
결과 : Overall, 87/118 received FCBT and 31/118 received FCBT + bimatoprost. In those groups, mean IOP reductions from baseline (16.8 and 15.3 mmHg) at month 12 were 4.1 mmHg (24.0%) and 3.6 mmHg (23.6%) at 11 AM (both P<.0001), respectively, and similar at 9 AM, with VF progression rates ≤0.17%/year (P≥.8367 vs baseline). In NTG patients who received FCBT (n=66/93) or FCBT + bimatoprost (n=27/93), mean IOP reductions from baseline (15.8 and 14.9 mmHg) at month 12 were similar at 11 AM (22.4% and 23.1%; P<.0001) and 9 AM, with VF progression rates ≤1.15%/year (P≥.1955 vs baseline).
결론 : Among all patients receiving FCBT alone, 77/87 (88.5%) achieved target IOP in 1 month (mean); those requiring bimatoprost generally had lower baseline IOP, initiating treatment 89 days (average) after starting FCBT.
Despite a mean baseline IOP <17 mmHg, FCBT (with/without bimatoprost) significantly reduced IOP in the overall and NTG populations. Target IOP was achieved early and sustained (12 months). No VF deterioration or unexpected AEs were documented, supporting FCBT as effective treatment for POAG including NTG.
|